Utilidad de la detección de anticuerpos anti-factor VIII por Elisa en hemofílicos

Blanco, Alicia N; Kempfer, Ana C; Varela, Claudia P; Grosso, Silvia; Pérez Bianco, Raúl; Lázzari, María A.
Bol. Acad. Nac. Med. B.Aires ; 76(2): 387-96, jul.-dic. 1998. graf
Artículo en Español | BINACIS | ID: bin-15344

Documentos relacionados

  1. Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.
  2. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
  3. Inhibitors: A Need for Eradication?
  4. Inhibitor screening in non-severe haemophilia patients; a major challenge.
  5. Advances in knowledge of inhibitor formation in severe haemophilia A.
  6. Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.
  7. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.
  8. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
  9. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.
  10. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors.